Abstract:Pancreatic ductal adenocarcinoma (PDAC), a leading cause of cancer mortality in the United States, presents significant treatment challenges due to its late diagnosis and poor prognosis. Despite advances, the five-year survival rates remain dismally low, with only a fraction of patients eligible for potentially curative surgical interventions. This review aims to comprehensively examine the current landscape of targeted therapies in PDAC, focusing on recent developments in precision medicine approaches. We explore various molecular targets, including KRAS mutations, DNA damage repair deficiencies, mismatch repair pathway alterations, and rare genetic fusions. The review discusses emerging therapies, such as PARP inhibitors, immune checkpoint inhibitors, and novel targeted agents, like RET and NTRK inhibitors. We analyze the results of key clinical trials and highlight the potential of these targeted approaches in specific patient subgroups. Recent developments in PDAC research have emphasized precision oncology, facilitated by next-generation sequencing and the identification of genetic and epigenetic alterations. This approach tailors treatments to individual genetic profiles, improving outcomes and reducing side effects. Significant strides have been made in classifying PDAC into various subtypes, enhancing therapeutic precision. The identification of specific mutations in genes like KRAS, along with advancements in targeted therapies, including small molecule inhibitors, offers new hope. Furthermore, emerging therapies targeting DNA repair pathways and immunotherapeutic strategies also show promising results. As research evolves, integrating these targeted therapies with conventional treatments might improve survival rates and quality of life for PDAC patients, underscoring the shift towards a more personalized treatment paradigm.

Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer

Pancreatic Cancer from Molecular Pathways to Treatment Opinion

The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

[Molecular Targeted Therapy Strategy and Clinical Research Progress in Pancreatic Ductal Adenocarcinoma].

Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling

Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review

Research Progress of Targeting Therapy of Pancreatic Cancer

Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions

Target and Gene-Based Therapeutic Strategies against Pancreatic Cancer: Current and Future Prospects

Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer

Insight of Pancreatic Cancer: Recommendations for Improving Its Therapeutic Efficacy in the Next Decade

Emerging pathways and future targets for the molecular therapy of pancreatic cancer

Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy

Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology

Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment

Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond

New Molecular Targets for Therapy

Advances in targeted therapy for pancreatic cancer

Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature